5XXI

Crystal structure of CYP2C9 in complex with multiple losartan molecules


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.204 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9

Maekawa, K.Adachi, M.Matsuzawa, Y.Zhang, Q.Kuroki, R.Saito, Y.Shah, M.B.

(2017) Biochemistry 56: 5476-5480

  • DOI: 10.1021/acs.biochem.7b00795
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Single-nucleotide polymorphisms in drug-metabolizing cytochrome P450 (CYP) enzymes are important contributors to interindividual differences in drug metabolism leading to adverse drug reactions. Despite their extensive characterization and importance ...

    Single-nucleotide polymorphisms in drug-metabolizing cytochrome P450 (CYP) enzymes are important contributors to interindividual differences in drug metabolism leading to adverse drug reactions. Despite their extensive characterization and importance in pharmacogenetics of clinical drugs, the structural basis of CYP polymorphisms has remained scant. Here we report the crystal structures of human CYP2C9 and its polymorphic variants, *3 (I359L) and *30 (A477T), with an antihypertensive drug losartan. The structures show distinct interaction and occupation of losartan in the active site, the access channel, and the peripheral binding site. The I359L substitution located far from the active site remarkably altered the residue side chains near the active site and the access channel, whereas the T477 substitution illustrated hydrogen-bonding interaction with the reoriented side chain of Q214. The results yield structural insights into the reduced catalytic activity of the CYP2C9 variants and have important implications for understanding genetic polymorphisms in CYP-mediated drug metabolism.


    Organizational Affiliation

    Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts , Kodo, Kyotanabe, Kyoto 610-0395, Japan.,Japan Atomic Energy Agency , 2-4 Shirane Shirakata, Tokai-mura, Ibaraki 319-1195, Japan.,Department of Pharmaceutical Sciences, University of Connecticut , Storrs, Connecticut 06267, United States.,Division of Medicinal Safety Science, National Institute of Health Sciences , Kamiyoga 1-18-1, Setagaya, Tokyo 158-8501, Japan.,National Institutes for Quantum and Radiological Science and Technology , 2-4 Shirane Shirakata, Tokai-mura, Ibaraki 319-1106, Japan.,Department of Integrative Structural and Computational Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States.,Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences , 106 New Scotland Avenue, Albany, New York 12208, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Cytochrome P450 2C9
A
463Homo sapiensMutation(s): 1 
Gene Names: CYP2C9 (CYP2C10)
EC: 1.14.14.-
Find proteins for P11712 (Homo sapiens)
Go to Gene View: CYP2C9
Go to UniProtKB:  P11712
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
K
Query on K

Download SDF File 
Download CCD File 
A
POTASSIUM ION
K
NPYPAHLBTDXSSS-UHFFFAOYSA-N
 Ligand Interaction
HEM
Query on HEM

Download SDF File 
Download CCD File 
A
PROTOPORPHYRIN IX CONTAINING FE
HEME
C34 H32 Fe N4 O4
KABFMIBPWCXCRK-RGGAHWMASA-L
 Ligand Interaction
LSN
Query on LSN

Download SDF File 
Download CCD File 
A
[2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
Losartan
C22 H23 Cl N6 O
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.204 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 74.571α = 90.00
b = 142.958β = 90.00
c = 161.420γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data reduction
SCALAdata scaling
PHASERphasing
REFMACrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
JapanKAKENHI22590054, KAKENHI25293128

Revision History 

  • Version 1.0: 2017-10-25
    Type: Initial release
  • Version 1.1: 2017-11-15
    Type: Database references
  • Version 1.2: 2017-12-13
    Type: Database references